ONCOCROSS
Oncocross, a Seoul-based AI drug discovery and development biotech, announced on May 22nd that it has signed a joint research agreement with JW Pharmaceutical to develop new drugs based on the AI platform.
Under this contract, the two companies will join research efforts to identify and verify development possibilities for new indications for the 'first-in-class' drug pipeline that JW Pharmaceutical is developing in the area of anticancer and regenerative medicine.
For this purpose, Oncocross’s proprietary AI platform RAPTOR AITM will be utilized. RAPTOR AITM is an AI drug development platform that screens the optimal or additional indications for drug candidates or existing drugs. The platform provides AI capabilities necessary for pharmaceutical companies' new drug development, resulting in higher accuracy, reduced cost, and shorter development time compared to traditional methods.
Previously, the two companies signed a joint research agreement to identify new indications for drug candidates in 2022. Through this joint research, JW Pharmaceutical has secured positive data on expanding an orphan disease indication for the new drug candidate and is establishing a follow-up development plan.
Having previously verified the RAPTOR AITM technology, JW Pharmaceutical once again expects to reduce the time required for new indication screening and increase the probability of success in clinical studies for the 'first-in-class' drug pipelines.
JW Pharmaceutical said, “The level of innovation we are focusing on requires high R&D capabilities and substantial costs and time to discover new drug candidates and indications,” adding, “We will continue to pursue diverse partnerships with innovative local and global biotech companies that possess new technologies such as Oncocross.”
Dr. Yirang Kim, CEO of Oncocross commented, "This follow-on collaboration is significant in the sense that the utility and commercial value of RAPTOR AITM has been recognized in the market.” He further added, “We will continue to do our best to set examples of collaboration between large pharmaceutical companies and biotech in the AI drug development field.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528528566/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Textron Aviation Broadens Aftermarket Connectivity Solutions for Cessna Citation Latitude by Offering Starlink High-Speed Internet18.9.2025 15:30:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced an additional high-speed internet connectivity solution for the Cessna Citation Latitude following the Federal Aviation Administration’s (FAA) issuance of AeroMech’s Supplemental Type Certificate (STC) for Starlink high-speed internet connectivity. AeroMech’s STC utilizes Starlink’s constellation of Low Earth Orbit (LEO) satellites to provide more reliable connectivity over land, water and remote areas, where traditional in-flight Wi-Fi may not have service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918380069/en/ Textron Aviation broadens aftermarket connectivity solutions for Cessna Citation Latitude by offering Starlink high-speed internet (Photo Credit: Textron Aviation) “With Starlink connectivity now available as an upgrade, Citation Latitude customers can enjoy a seamless, high-speed in-flight experience that keeps them connected in more
Lenovo Finds 65% of IT Leaders Admit Their Defenses Can’t Withstand AI Cybercrime18.9.2025 15:00:00 CEST | Press release
New Lenovo Research Shows How AI-Powered Defenses Help Enterprises Turn Cyber Risk into Cyber Resilience Lenovo research reveals a widening security gap as AI-driven cybercrime surges: 65% of IT leaders surveyed admit their defenses are outdated and unable to withstand AI-enabled attacks, and just 31% feel confident defending against them. The new insights are drawn from Lenovo’s third Work Reborn report, Reinforcing the Modern Workplace. While AI is driving business improvements and efficiency gains, it is also fueling a new wave of cybercrime that most businesses are ill-equipped to defend against. This underscores the critical need for enterprises to adopt AI-driven strategies that can counter threats that learn, adapt, and evolve in real time. Lenovo is positioned to deliver this shift with end-to-end solutions that embed AI security into the digital workplace. With operations in 180 markets and a leader in enterprise technology, Lenovo brings unmatched scale to solving AI workplac
Decode the Future of AI and Customer Experience at Elevate'25 Digital Innovation Summit18.9.2025 15:00:00 CEST | Press release
With keynotes from Google Cloud and an independent research firm, Elevate’25 will provide actionable strategies to harness the power of AI and create exceptional experiences for today's mobile-first consumer As unprecedented advancements in AI reshape consumer behavior, digital innovation summit Elevate'25 opened for general registration today. Sponsored by Airship, the exclusive, one-day event is designed to equip business leaders with proven strategies to harness artificial intelligence and mobile-first technology for a decisive competitive advantage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918928987/en/ Gain insight and advice from firms at the frontier of AI-powered, mobile-first customer experiences. Taking place on October 15, 2025, at the iconic Shangri-La at The Shard in London, Elevate'25 moves beyond the headlines to provide a practical roadmap for success, featuring insights from brand executives and ind
Armis Receives Morgan Stanley 2025 Innovation Award18.9.2025 15:00:00 CEST | Press release
Armis Centrix™ Platform, powered by Armis’ AI driven cyber security intelligence engine, manages over 6.5 billion assets daily making it the largest of its kind in the world Armis, the cyber exposure management & security company, today announced that it has received the prestigious Innovation Award from Morgan Stanley at the Firm’s 23rd Tech Week event in Silicon Valley. For over 20 years, Morgan Stanley has celebrated companies with innovative capabilities that have materially impacted its business. Armis is being recognized for its partnership with Morgan Stanley, which chose Armis to help protect and secure its critical internet-of-things (IoT) assets across its organization. “Continuous and cutting-edge innovation that enables global cybersecurity teams to combat malicious actors is essential in today’s environment. The attack surface is growing exponentially, and Armis’ mission is to protect organizations’ entire attack surface by managing cyber risk exposure in real time,” said
Scoring Big With Fans: Balchem Spotlights the Power of Vitamin K2 at FC Bayern Women’s Season Opener18.9.2025 14:33:00 CEST | Press release
Balchem, a leading global manufacturer of specialty ingredients for human nutrition and health – and official partner of FC Bayern (FCB) Women’s football team - has launched its first ever direct-to-consumer initiative, showcasing the power of vitamin K2 to FCB fans. The company promoted its K2VITAL™ brand with an exhibition stand at the Allianz Arena in Munich, during the opening game of the Bundesliga (German football league) on 6 September. This initiative is part of Balchem’s latest marketing strategy, which aims to raise consumer awareness of the health benefits vitamin K2 has to offer, bridging the gap between B2B and B2C markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918950889/en/ Balchem Spotlights The Power of Vitamin K2 at FC Bayern Women’s Season Opener Co-Branded K2 Health Vitamins Hit the Pitch The opening event of the season provided a unique platform for Balchem to promote K2VITAL™, a patented, typ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom